CD80 and autoimmune disease: The therapeutic efficacy of inhibiting DC:T-cell interactions in multiple autoimmune diseases has already been shown using Abatacept which binds to CD80/86 on DCs, preventing the co-stimulatory signal required for T-cell activation [54,55].